Mast Therapeutics Inc (NASDAQ:MSTX) has earned an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus target price of $2.67 for the company and are predicting that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also assigned Mast Therapeutics an industry rank of 92 out of 265 based on the ratings given to related companies.

A number of equities research analysts have issued reports on MSTX shares. Maxim Group reaffirmed a “buy” rating and set a $5.00 price objective on shares of Mast Therapeutics in a report on Thursday, June 9th. Zacks Investment Research downgraded Mast Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 12th. Roth Capital restated a “buy” rating and issued a $2.00 price target on shares of Mast Therapeutics in a research report on Monday, August 1st. Finally, Canaccord Genuity restated a “buy” rating and issued a $3.00 price target on shares of Mast Therapeutics in a research report on Thursday, July 28th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of Mast Therapeutics (NASDAQ:MSTX) traded down 0.3737% during midday trading on Tuesday, hitting $0.5865. 2,494,198 shares of the stock were exchanged. Mast Therapeutics has a 52-week low of $0.21 and a 52-week high of $0.71. The firm’s market cap is $124.23 million. The firm’s 50-day moving average is $0.45 and its 200 day moving average is $0.38.

Mast Therapeutics (NASDAQ:MSTX) last released its earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. On average, analysts forecast that Mast Therapeutics will post ($0.21) earnings per share for the current year.

An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. raised its stake in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent reporting period.

Mast Therapeutics Company Profile

5 Day Chart for NASDAQ:MSTX

Get a free copy of the Zacks research report on Mast Therapeutics (MSTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with's FREE daily email newsletter.